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Pooled human immunoglobulin labeled with indium-111 (111ln- 
HlgG) was used to identify the presence and extent of infection 
in patients positive for human immunodeficiency virus (HIV), 
presenting with either symptoms and/or signs of acute chest 
infection or with pyrexia without localizing signs or symptoms. 
Fifty-five studies were performed in 51 patients with suspected 
chest infection or pyrexia without localizing signs. Of these, 
1111n-HIgG identified intrapulmonary accumulation in 17 patients 
with Pneumocystis carinii pneumonia, eight with bacterial pneu­
monia, five with cytomegalovirus pneumonia, three with pulmo­
nary Mycobacterium avium intracellulare infection and one with a 
fungal pneumonia. There was no intrapulmonary accumulation 
of 111ln-HlgG in five patients with bronchopulmonary Kaposi’s 
sarcoma and in three patients with intrathoracic lymphoma. 
Quantification of lung/heart activity was significantly increased (p 
< 0.05) in patients with active chest infection compared with 
those with intrapulmonary tumor or no active lung pathology. 
Indium-111 -HlgG scintigraphy also localized at 14 sites of extra- 
pulmonary infection, including six patients with colitis. There 
were no false-negative studies but false-positive uptake was 
seen in four studies. These results confirm that 111ln-HlgG cor­
rectly identifies the presence and extent of infection in patients 
positive for HIV antibody.
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TA  he diagnosis of infection in patients with human immu­
nodeficiency virus (HIV) infection and those with acquired 
immunodeficiency syndrome (AIDS) is frequently ham­
pered by the nonspecific nature of presenting symptoms 
and signs. Conventional imaging techniques such as chest 
radiographs and x-ray-computed tomography (CT), al-
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though sensitive, may fail to demonstrate abnormalities in 
the presence of active infection (1-3). Conventional imag­
ing may not distinguish changes due to infection from those 
secondary to Kaposi’s sarcoma.
Functional imaging with 67Ga-citrate has proven useful 
in the investigation of HIV-positive patients with focal and 
diffuse infections. The technique is at its most useful in 
distinguishing Pneumocystis carinii pneumonia (PCP) from 
bronchopulmonaiy Kaposi’s sarcoma (4,5). Intrapulmo­
nary accumulation of 67Ga-citrate is not specific for PCP 
and uptake is also seen in several other pathologies includ­
ing lymphoma (6). The presence of physiological bowel 
uptake, which may be increased in patients with AIDS, 
further reduces the utility of 67Ga-citrate in identifying in­
traabdominal sepsis or colonic infection (7).
Pooled human immunoglobulin (HlgG) labeled with 
H1In or " mTc has been shown to have a high sensitivity 
and specificity in localizing infection in immune competent 
patients (8-10). Like 67Ga-citrate it has the advantage of 
simple intravenous injection, in contrast to labeled autolo­
gous white cells in which extensive handling of blood prod­
ucts is required. Unlike 67Ga-citrate there is only minimal 
physiological bowel uptake of ln In-HIgG. In steroid-im- 
munosuppressed rats with PCP imaging with m In-HIgG 
demonstrated higher sensitivity than imaging with 67Ga- 
citrate (II).
The aim of this study was to determine the efficacy of 
lllIn-HIgG in identifying the presence and extent of infec­
tion in HIV-positive patients presenting with either symp­
toms and/or signs of acute chest infection or pyrexia with­
out localizing symptoms or signs.
METHODS AND MATERIALS
We prospectively studied consecutive HIV-positive patients 
presenting with suspected infection. Patients were included in the 
trial if they: (1) had signs or symptoms suggestive of chest infec­
tion in which initial investigations, including chest radiology,
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blood chemistry, full blood count, blood and sputum cultures, had 
failed to provide a diagnosis; and (2) had pyrexia for at least four 
days without localizing signs or symptoms, and simple investiga­
tions such as radiology, ultrasound, blood chemistry, full blood 
count and culture of blood, sputum, urine or feces were nondiag­
nostic.
All patients gave informed written consent for participation in 
the study, and the protocol was approved by the Clinical Inves­
tigation Committee of the Middlesex Hospital and the Adminis­
tration of Radioactive Substances Advisory Committee (AR- 
SAC). Fifty-five studies were performed in 51 patients (50 males); 
mean age was 32 (range 1 8 -5 7 )  yr. Two patients had a second 
study performed after intervals of 2 and 5 mo, and one patient had 
three studies over a 7-mo period. These repeat studies were car­
ried out because the patients presented with new symptoms or a 
recurrence of old symptoms. Thirty-eight studies were performed 
for suspected chest infection and 17 for pyrexia without localizing 
features.
Radiopharmaceutical
Pooled nonspecific human polyclonal immunoglobulin G (San- 
doglobulin, Sandoz AG, Nürnberg, Germany), which was nega­
tive for HIV and Hepatitis B surface antigen was conjugated with 
diethylenetriamine pentacetic acid (DTPA). The conjugated solu­
tion was sterilized by gel filtration and aliquots of 0.5 ml and 
stored at -20°C  in sterile glass vials until used. For each study, a 
vial was allowed to thaw and conjugated with m In chloride 
(Mallinckrodt Medical, Petten, The Netherlands) (12). A dose of 
0 .2 5 -0 .5  mg of human immunoglobulin labeled with 1 mCi (37 
MBq) of 11 *In in a volume of 0.3 -  0.5 ml was used for each study 
and injected intravenously into the antecubital vein of the non­
dominant arm.
Imaging Protocol
Using an IGE 400AC Starcam gamma camera and computer 
(IGE International, Radlett, Berkshire UK) anterior and posterior 
planar images of the abdomen, pelvis and chest were obtained at 
4,24 and 48 hr after injection o f 11 ‘In-HIgG. The camera was fitted 
with a medium-energy parallel-hole collimator. Images were col­
lected in digital form into a 128 x 128 matrix. Two photopeaks, 
173 and 247 keV, each with 20% windows, were used. Each image 
was acquired for 600k counts and formatted onto x-ray film for 
reporting. Each image was obtained in about 4 - 6  min.
Qualitative Analysis of Studies
The 4, 24 and 48-hr images from each study were reported 
independently by two observers who were blind to patient clinical 
diagnosis and laboratory results. A study was considered positive 
if both observors agreed there was diffuse or focal accumulation 
o f 11 ‘in-HIgG in the lungs equal or greater than surrounding bone 
marrow or surrounding soft tissue activity in neck or shoulder 
(intrapulmonary). If bone marrow activity was absent, compari­
son was made to soft tissue alone. A study was also considered 
positive if both observors agreed there was focal accumulation at 
any site in the chest outside the lungs, abdomen or pelvis greater 
than surrounding soft tissue (extrapulmonary). If there was dis­
agreement between the two observors, the study was considered 
negative.
Results of m In-HIgG scans were compared in all studies with 
the final diagnosis obtained by microbiological and histological 
investigations of blood, urine and sputum, including expressed 
sputums, bronchoalveolar lavage fluid and feces. Results of each 
study also were compared to information obtained by other in-
FIGURE 1. Regions of interest used to calculate the geometric 
mean of the lung-to-heart ratio of 111ln-HlgG activity.
vestigations, including upper gastrointestinal endoscopy, colonos­
copy, open biopsy and CT-guided percutaneous biopsy. All pa­
tients had undergone chest x-ray in the 48 hr before or after 
initiation of the u l In-HIgG study.
Only histological or microbiological data were used for com­
parison with m In-HIgG images.
Quantitative Analysis
Instead of a subjective grading of lung uptake, a quantitative 
analysis of intrapulmonary accumulation of m In-HIgG was cal­
culated using the 48-hr images in all studies. This was done using 
the geometric mean of lung activity obtained by using a 10 x 10 
pixel (31.2 mm x 31.2 mm) region of interest (ROI), placed in the 
upper, middle (avoiding the hilum) and lower thirds of the right 
lung on both the anterior and posterior images of the chest (Fig. 
1). The left lung was not used to quantify lung activity as it was 
impossible to draw ROIs in the lower third of the lung that did not 
include activity in the heart. The mean-lung activity was normal­
ized to blood-pool activity by dividing the geometric mean of lung 
activity by the geometric mean of activity in the left ventricle 
(derived by using a 10 x 10 pixel ROI drawn over the heart in both 
anterior and posterior images).
The resulting lung-to-heart ratio was calculated for the different 
groups of studies; those in patients with PCP, those with pulmo­
nary infection due to other causes, those with intrapulmonary 
tumor and studies of patients with no acute chest disease. The 
mean lung-to-heart ratio at 48 hr in those patients with PCP and 
those with infection due to other causes was compared with the 




Seventeen cases of PCP were confirmed, in which all 
patients had abnormal pulmonary uptake of n iIn-HIgG 
(Fig. 2, Table 1). Positive pulmonary uptake of ln In-HIgG 
was also found in 20 cases of pulmonary infection due to 
other causes, including bacterial infection (eight studies), 
pulmonary Mycobacterium avium intracellulare (MAI) (six 
studies) cytomegalovirus (five studies) and fungal infection 
(one study). Images taken 48 hr postinjection provided the 
most positive images of infection, although 24-hr images 
were scored positive in all studies. Images at 4 hr postin­
jection were not helpful.
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FIGURE 2. Patient with Pneumocystis carinii pneumonia and a normal chest x-ray (A) but with diffuse intrapulmonary accumulation of 
111ln-HlgG seen (B) 48 hr postinjection. This is compared with a 48-hr anterior chest image in a patient with no pulmonary disease (C).
Eight studies, including five in patients with bronchopul­
monary Kaposi’s sarcoma and three in patients with ex­
tensive intrapulmonary B-cell lymphoma, had no coexist­
ent pulmonaiy infection. In all studies there was no 
elevated uptake of in In-HIgG in the lungs (Fig. 3). Of the 
ten patients in whom no intrapulmonary disease was con­
firmed, only one patient, who had endstage renal failure, 
had diffuse pulmonary accumulation of in In-HIgG.
In the 17 cases of PCP, there was evidence of diffuse 
pulmonary accumulation of in In-HIgG in 14 cases, as op­
posed to evidence on x-ray of diffuse changes in only six of
TABLE 1
Intrapulmonary Accumulation of 111ln-HlgG in 55 Studies
Diagnosis
111ln-HlgG study result 
Positive Negative
Intrapulmonary disease
Pneumocystis carinii pneumonia 17 0
Bacterial pneumonia* 8 0
Mycobacterium avium intracellulare 6 0
Cytomegalovirus 5 0
Fungal pneumonia (Aspergillus sp) 1 0
Bronchopulmonary Kaposi’s sarcoma 0 5
Intrapulmonary lymphoma sarcoma 0 3
No pulmonary disease 1 9
*Causative agents were Haemophilus influenzae (n = 4), Streptococ­
cus pneumoniae (n = 3) and Cyptococcus neoformans (n = 1).
14 cases, focal abnormalities in two of the cases, and nor­
mal readings in the remaining six. In the other three of 17 
cases, both lu In-HIgG and chest x-ray revealed focal ab­
normalities. In four cases of pulmonary infection due to 
other causes, n iIn-HIgG showed diffuse intrapulmonary 
uptake while chest x-rays were normal. In these four cases 
the organisms of infection were MAI (two cases), Haemo­
philus influenzae (one case) and cytomegalovirus (one 
case).
Quantitative Analysis
Quantitative analysis of lung/heart activity confirms the 
qualitative data and demonstrates a significantly increased 
lung-to-heart ratio of m In-HIgG at 48 hr postinjection in 
patients with chest infection due to both PCP and other 
causes, compared with patients in whom there was no 
intrapulmonary disease (Table 2). There was no significant 
difference in the lung-to-heart ratio of in In-HIgG in pa­
tients with intrapulmonary neoplasia such as Kaposi’s sar­
coma and B-cell lymphoma and in patients with no in­
trapulmonary disease.
Extrapulmonary Disease
Uptake of n lIn-HIgG outside the lungs (extrapulmo­
nary) was seen in 13 cases (Table 3). Colitis/proctitis was 
correctly identified in all six cases in which it was con­
firmed histologically. One patient had bacterial pericardi­
tis, one had sinusitis and one had an unsuspected ishiorec- 
tal abscess; all were correctly identified by n iIn-HIgG
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FIGURE 3. Patient with bronchopulmonary Kaposi’s sarcoma and a grossly abnormal chest x-ray (A) but with no pulmonary accumu­
lation of 111ln-HlgG (B) seen 48 hr postinjection.
£
(Fig. 4). In one patient with colitis and in the patient with 
ishiorectal abscess, coexistent pulmonary infection was 
present and correctly identified.
In four cases there was positive accumulation of m In- 
HlgG in the absence of infection. In the patient with end- 
stage renal disease who had diffuse lung accumulation of 
n iIn-HIgG, diffuse abdominal accumulation of in In-HIgG 
also occurred. In two patients with B-cell lymphoma, there 
was colonic accumulation o f 11 ’in-HIgG but no histological 
evidence of colon involvement by either infection or tu­
mor. In the fourth case, ln In-HIgG accumulated at the site 
of a sterile hematoma secondary to a stab wound.
DISCUSSION
Results demonstrate that 11 'in-HIgG can identify a wide 
range of infection in HIV-positive patients, including bac­
teria, fungi and viruses. The sensitivity of in In-HIgG was 
high (100%) in the chest with no false-negative studies. It is 
known that 67Ga-citrate has a sensitivity greater than 90% 
in localizing chest infection in HIV-positive patients
TABLE 2




Pneumocystis carinii pneumonia 17 0.66 (0.05)*
All other causes of pulmonary 20 0.59 (0.09)*
infection
No pulmonary disease 10 0.51 (0.04)
Pulmonary tumor 8 0.51 (0.07)t
Data displayed as mean (± s.d.). Using student's t-test difference in
lung/heart activity in these groups compared with those studies in which
no intrapulmonary disease was present was * significant (p < 0.05) o rf
not significant.
(4,5,13) and these results are therefore comparable. As 
previously reported in a small number of HIV-negative 
patients and in immunosuppressed rats, the predominant 
pattern of in In-HIgG seen with PCP was diffuse intrapul- 
monary activity (DIPA) (8,11). This distribution, seen in 14 
of 17 patients with PCP is similar to that reported using 
h7Ga-citrate in this disease (4,5).
The use of in In as the radiolabel allows longer imaging 
times than other radiolabels such as " mTc. This may ex­
plain why the 100% sensitivity for identifying pulmonary 
infection obtained in this series was higher than the 33% 
obtained in a previous study that used " mTc to label HIgG 
(74). It is known that n iIn-HIgG will accumulate in sites of 
infection in HIV-negative patients but not in immunocom­
promised patients (15) and imaging is required beyond the 
24-hr limit set by the short physical half-life of " mTc. This 
is probably because significant blood-pool activity, obscur­
ing any infection is still present in the chest at 24 hr postin­
jection but clears by 48 hr. This was confirmed in our study
TABLE 3





Ischiorectal abscess 1 0
Infected axillary lymph node 1 0
Bacterial pericarditis 1 0
Sinusitis 1 0
No extrapulmonary infection 4* 41
*One patient with renal failure, one with noninfected hematoma and
two with lymphoma had unexplained colonic activity in the absence of
colonic disease.
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FIGURE 4. Intense accumulation of 111ln-HlgG seen 48 hr 
postinjection, extending from the rectum into the right buttock. At the 
time of scanning only minimal symptoms had developed at site but 
over 1 liter of pus was removed at operation 24 hr later.
where the images performed 48 hr postinjection were the 
most useful.
The tracer lu In-HIgG has an advantage over 67Ga cit­
rate in that it does not accumulate in lymphoma, which was 
present in three of our patients. This has also been noted in 
previous studies on HIV-negative patients with lymphoma 
(8,15). Like 67Ga-citrate, the presence of 1 n In-HIgG in the 
chest of a patient with bronchopulmonary Kaposi’s sar­
coma is indicative of superimposed infection, and is par­
ticularly useful when chest x-ray is abnormal and therefore 
limited in its use diagnostically. Tracer m In-HIgG activity 
at sites of noninfected inflammation have been reported 
and occurred in one of our patients with splenic-bed hema­
toma (5). Two patients with lymphoma had colonic H1In- 
HlgG activity but no evidence of lymphoma or of infection 
in the colon on biopsy. The cause is unknown but has been 
reported in patients with neutropenia after administration 
of m In-HIgG and WmTc-HIgG in patients with lymphoma 
(14) and may be due to protein leakage in the lumen of 
these patients (75).
The ability to image intrapulmonary infection at 48 hr 
postinjection, confirmed by significantly increased lung-to- 
heart ratio of in In-HIgG activity, may offer advantages 
over 67Ga-citrate where images at 72 hr postinjection may 
be needed to confirm presence of chest infection (1,14). 
Furthermore, the estimated radiation burden to patients 
from in In-HIgG is less than that from 67Ga-citrate (16,17). 
However, before in In-HIgG can replace 67Ga-citrate as 
the agent of choice in identifying infection in HIV-positive 
patients, a more direct comparison of the two agents is 
required.
This study demonstrates that m In-HIgG, which has
proven diagnostic utility in neutropenic patients, can accu­
rately identify infection from a wide range of pathogens 
within and outside the lungs in HIV-positive patients and 
patients with AIDS who present with respiratory symp­
toms or pyrexia of undetermined origin. If subsequent 
studies confirm these findings, m In-HIgG may replace 
67Ga-citrate as the scintigraphic method of choice in these 
patients.
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